Modified Glasgow prognostic score predicts outcomes of tyrosine kinase inhibitor monotherapy and immune checkpoint inhibitor combination therapy for metastatic renal cell carcinoma
The mGPS effectively predicted the oncological outcomes for mRCC. In particular, it may help identify patients with high mGPS who could benefit from ICI combination therapy.
Authors
- Keisuke Goto (ORCID: https://orcid.org/0000-0002-4165-1809)
- Nobuyuki Hinata (ORCID: https://orcid.org/0000-0001-7014-6812)
- Yoshito Kagiyama
- Yoshimasa Kurimura
- Kensuke Nishida
- Kenichiro Fukuoka (ORCID: https://orcid.org/0000-0002-4849-0614)
- Takashi Babasaki (ORCID: https://orcid.org/0000-0002-7792-8507)
- Yasushi Orihashi (ORCID: https://orcid.org/0000-0002-5605-947X)
- Kenichiro Ikeda (ORCID: https://orcid.org/0000-0002-3174-8738)
- Kazuma Yukihiro
- Kohei Saito (ORCID: https://orcid.org/0000-0002-0589-9479)
- Hideo Iwamoto
- Kunihiro Hashimoto
- Takeshi Ueno
- Akira Fujita
- Nanami Taketomi
Institutions
- Hiroshima University (JP)
- Fukuyama University (JP)
- Hiroshima General Hospital (JP)
- Hiroshima City Asa Citizens Hospital (JP)
- Hiroshima Prefectural Hospital (JP)
- Fukuyama City Hospital (JP)
- Matsuyama Red Cross Hospital (JP)
- Fukuyama Cardiovascular Hospital (JP)
- Hiroshima University Hospital (JP)
- Higashihiroshima Medical Center (JP)
- Chugoku Rosai Hospital (JP)
- Miyoshi Kasei (Japan) (JP)
- Kure Medical Center (JP)
- Onomichi General Hospital (JP)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1016/j.urolonc.2025.07.018
- Citations
- 2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04